| Similar Articles |
|---|
 |
The Motley Fool
July 5, 2005
Bill Mann |
This Merger Deserves Revisiting Transkaryotic agreed to $37 per share from Shire Pharmaceuticals -- but that was before the good news rolled in. These shares are worth 30% more today. The market knows it.   |
The Motley Fool
June 6, 2005
Tim Beyers |
When Good Stocks Go Bad Dividends can be a lifeboat to a portfolio with shipwrecked stocks. Are you protected? |
The Motley Fool
April 21, 2005
Rich Duprey |
Poverty to Prosperity Even if you can only put away small amounts of money, you can still retire with a rich man's nest egg. |
The Motley Fool
December 15, 2003
Mathew Emmert |
Warren, Show Me the Money Why Berkshire Hathaway should pay dividends. |
The Motley Fool
December 30, 2004
Paul Elliott |
Why Daddy Loves This Stock Investing a friend's hard-earned money can be every bit as unnerving as investing your own. Let's take a look at Protein Design Labs, the leader in antibody humanization technology. |
The Motley Fool
August 10, 2005
Nathan Parmelee |
Your Biggest Advantage Take your time, get wealthy slowly, and enjoy life. Everyone wants to find the next double, triple, or 10-bagger. But the true spoils go to those who invest early and often. |
The Motley Fool
June 24, 2005
Nathan Parmelee |
The Easiest Double Investors looking to double their money should consider taking a walk down the value path. The easiest doubles to find in the market are not the high-flying growth companies, but the consistent slow growers trading at a short-term discount. |
The Motley Fool
March 20, 2006
Jeremy MacNealy |
Not-So-Friendly Performance Friendly Ice Cream dishes out lackluster results for the fourth quarter. Investors, take note. |
The Motley Fool
June 8, 2006
Chuck Saletta |
Stocks You Won't Sell If the companies you own pay you well, you may never need to sell them. |
The Motley Fool
August 22, 2005
Stephen D. Simpson |
Get Real, Get It Together, and Get Going Taking personal responsibility for investing your money can be a daunting task. Wall Street is a scary and confusing place, but like a trip to the doctor, it can be essential to your long-term well-being. |
The Motley Fool
March 22, 2005
Travers & Djuranovic |
Stock Madness 2005: Protein Design Labs vs. Taser One keeps you healthy; the other keeps you safe. But which one will make your portfolio happier? "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness shows the way. |
The Motley Fool
January 20, 2005
John Reeves |
Making a Million Over Coffee How one soaring stock can rescue you from your bad decisions. |
The Motley Fool
November 21, 2007
Anand Chokkavelu |
Black Friday Bargain Stock: Cemex Is Cemex a good value right now? The international cement-maker has been beaten down by the market -- unfairly, perhaps -- for its ties to the U.S. housing market. |
The Motley Fool
September 13, 2007
Mac Greer |
Fool Video: Buffett's Next Stock and Steve Jobs' Hard Drive What will Warren Buffett buy next? Should Starbucks market to kids? Is Steve Jobs a Machiavellian genius? These stories are discussed in this video. |
The Motley Fool
March 30, 2005
Travers & Smith |
Stock Madness 2005: Protein Design Labs vs. Plum Creek Timber This biotech isn't as risky as you might think. But is it as solid as a tree company? Find out in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
February 2, 2005
John Reeves |
Searching for 40,000% Returns Growth investing is highly volatile and will fray the nerves of those individuals with a low risk tolerance. That said, everyone should devote a portion of his or her portfolio to growth stocks. |
The Motley Fool
July 21, 2005
Bill Mann |
Been Caught Stealing There's nothing wrong with taking investing ideas from others, so long as you still do the work. |
The Motley Fool
July 26, 2005
Gardner & Mann |
For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals. |
The Motley Fool
August 30, 2005
Nathan Parmelee |
Kings, Fools, and CEOs Investors spend a great deal of time on a company's numbers and results, particularly on a quarterly basis, but it is just as important to understand the history of a company's management and what drives them. |
The Motley Fool
July 30, 2010
Mac Greer |
Starbucks' Future: Short, Tall, or Venti? The coffee giant has a lot of options. |
Entrepreneur
January 2006
April Y. Pennington |
Cream of the Crop Cold Stone Creamery's chairman and CEO discusses how consummate customer service sets his company apart from the competition. |
The Motley Fool
September 29, 2005
Rick Aristotle Munarriz |
Dueling Fools: Baidu.com Bull Rebuttal It's hard to deny the potential of China's developing market over our own established market. Look at where Yahoo! and Google were. Now look at where they stand. Is $2.5 billion still too much to pay for Baidu? Investors, take note. |
The Motley Fool
June 21, 2005
Charly Travers |
A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire. |
The Motley Fool
March 22, 2006
Charly Travers |
Stock Madness 2006: The Biotech Dream Team The rewards can cancel out the risks, and then some. Investors, who wins this round of the investing series based loosely on the annual NCAA College Basketball Tournament, a.k.a. "March Madness?" Amgen... Foxhollow Technologies... etc. |
The Motley Fool
March 28, 2005
Charly Travers |
Stock Madness 2005: Protein Design Labs vs. Yahoo! Two very different Rule Breakers face off in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
July 11, 2007
Rich Duprey |
Cemex, Rinker Cement a Deal The Mexican cement giant reaches a crucial 90% stake in an Australian rival. Investors, take note. |
The Motley Fool
May 24, 2004
Rich Smith |
Cement Flows Slow According to several news outlets, from local television stations in Florida to the venerable Wall Street Journal in NYC, America is in the midst of a shortage in an essential commodity -- cement. What stocks could benefit? |
The Motley Fool
September 27, 2006
David Meier |
Berkshire Hathaway Is Not for Everyone If you understand Berkshire thoroughly and believe it's a bargain today, go for it. If not, don't worry. There are plenty of great investment opportunities out there. |
The Motley Fool
June 21, 2004
Bill Mann |
On Time Not Wasted This reporter went back in time during his vacation, making a point to avoid checking up on the markets or his stocks at all. His verdict? He missed nothing at all. |
The Motley Fool
March 22, 2006
Tim Hanson |
Stock Madness 2006: Rage Against the Hype Machine Solid returns from solid companies are highlighted in this investing series based loosely on the annual NCAA College Basketball Tournament, a.k.a. "March Madness." Berkshire Hathaway... Valero... American Financial... etc. |
The Motley Fool
July 21, 2004
Rich Smith |
Dear Journal: What Were You Thinking? Younger investors would do well to ignore The Wall Street Journal's advice. |
The Motley Fool
July 25, 2005
Charly Travers |
Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged? |
The Motley Fool
April 27, 2005
Charly Travers |
Thanks for the Ride, Transkaryotic Selling was the right move, but it's hard to let go of stocks you like. Transkaryotic has certainly done very well for its shareholders. |
The Motley Fool
March 8, 2007
Chuck Saletta |
Dueling Fools: Berkshire Hathaway Bear Berkshire Hathaway trades at a premium to other insurers, is stingier to its shareholders than other conglomerates, and looks to be too cash-rich to invest its entire hoard successfully in the future. |
The Motley Fool
January 17, 2007
Tim Beyers |
The Best Retail Stock for 2007: Starbucks Starbucks is the best retail stock for 2007 because it's valued within reason, and because plenty of growth remains -- the company plans to more than triple its current global store count. |
The Motley Fool
December 10, 2004
Selena Maranjian |
Types of Investors: Which Are You? Knowing who you are can help you understand yourself and how you approach making money. Learn about some classifications of investors and which brokerage is right for you. |
